Eli Lilly & Co. has begun Phase I trials of anti-COVID-19 antibody candidate which could be used both as a treatment and a means of preventing infection.
The candidate LY-CoV555, is the lead antibody from Lilly's collaboration with Vancouver-based AbCellera, which has discovered and selected its lead...






